Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 5320.0
(1.92%)
KRW 5320.0
(1.92%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 18.52 Billion KRW | 138.63% |
| 2022 | 7.76 Billion KRW | -19.15% |
| 2021 | 9.6 Billion KRW | -22.26% |
| 2020 | 12.34 Billion KRW | 3.99% |
| 2019 | 11.87 Billion KRW | -46.85% |
| 2018 | 22.34 Billion KRW | 85.56% |
| 2017 | 12.04 Billion KRW | -39.71% |
| 2016 | 19.97 Billion KRW | 887.9% |
| 2015 | 2.02 Billion KRW | -17.84% |
| 2014 | 2.46 Billion KRW | 46.16% |
| 2013 | 1.68 Billion KRW | -47.49% |
| 2012 | 3.2 Billion KRW | 96.03% |
| 2011 | 1.63 Billion KRW | -40.8% |
| 2010 | 2.76 Billion KRW | 69.32% |
| 2009 | 1.63 Billion KRW | -75.72% |
| 2008 | 6.71 Billion KRW | -4.79% |
| 2007 | 7.05 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 828 Million KRW | -95.11% |
| 2024 Q1 | 16.94 Billion KRW | -8.51% |
| 2023 Q4 | 18.52 Billion KRW | 0.04% |
| 2023 Q3 | 18.51 Billion KRW | 148.09% |
| 2023 FY | 18.52 Billion KRW | 138.63% |
| 2023 Q2 | 7.46 Billion KRW | -2.24% |
| 2023 Q1 | 7.63 Billion KRW | -1.66% |
| 2022 Q2 | 13.96 Billion KRW | 46.97% |
| 2022 Q1 | 9.5 Billion KRW | -1.03% |
| 2022 FY | 7.76 Billion KRW | -19.15% |
| 2022 Q4 | 7.76 Billion KRW | -44.58% |
| 2022 Q3 | 14 Billion KRW | 0.29% |
| 2021 Q1 | 3.25 Billion KRW | -73.61% |
| 2021 Q3 | 9.67 Billion KRW | 224.49% |
| 2021 Q4 | 9.6 Billion KRW | -0.82% |
| 2021 FY | 9.6 Billion KRW | -22.26% |
| 2021 Q2 | 2.98 Billion KRW | -8.47% |
| 2020 Q1 | 11.56 Billion KRW | -2.63% |
| 2020 FY | 12.34 Billion KRW | 3.99% |
| 2020 Q2 | 12.51 Billion KRW | 8.2% |
| 2020 Q4 | 12.34 Billion KRW | -1.62% |
| 2020 Q3 | 12.55 Billion KRW | 0.32% |
| 2019 Q2 | 11.82 Billion KRW | -61.68% |
| 2019 Q3 | 12.07 Billion KRW | 2.1% |
| 2019 Q4 | 11.87 Billion KRW | -1.64% |
| 2019 FY | 11.87 Billion KRW | -46.85% |
| 2019 Q1 | 30.85 Billion KRW | 38.12% |
| 2018 Q4 | 22.34 Billion KRW | 1.03% |
| 2018 Q1 | 2.8 Billion KRW | -76.74% |
| 2018 FY | 22.34 Billion KRW | 85.56% |
| 2018 Q2 | 21.39 Billion KRW | 663.84% |
| 2018 Q3 | 22.11 Billion KRW | 3.37% |
| 2017 Q2 | 20.1 Billion KRW | 0.13% |
| 2017 Q4 | 12.04 Billion KRW | 0.88% |
| 2017 FY | 12.04 Billion KRW | -39.71% |
| 2017 Q3 | 11.93 Billion KRW | -40.63% |
| 2017 Q1 | 20.07 Billion KRW | 0.52% |
| 2016 Q3 | 19.3 Billion KRW | 62.46% |
| 2016 Q4 | 19.97 Billion KRW | 3.45% |
| 2016 Q1 | 5.44 Billion KRW | 169.44% |
| 2016 FY | 19.97 Billion KRW | 887.9% |
| 2016 Q2 | 11.88 Billion KRW | 118.15% |
| 2015 Q1 | 2.14 Billion KRW | -13.03% |
| 2015 Q4 | 2.02 Billion KRW | -7.95% |
| 2015 Q3 | 2.19 Billion KRW | -23.52% |
| 2015 FY | 2.02 Billion KRW | -17.84% |
| 2015 Q2 | 2.87 Billion KRW | 34.18% |
| 2014 Q2 | 1.07 Billion KRW | -22.26% |
| 2014 FY | 2.46 Billion KRW | 46.16% |
| 2014 Q4 | 2.46 Billion KRW | -4.01% |
| 2014 Q3 | 2.56 Billion KRW | 139.45% |
| 2014 Q1 | 1.37 Billion KRW | -18.21% |
| 2013 Q3 | 1.99 Billion KRW | -13.35% |
| 2013 Q4 | 1.68 Billion KRW | -15.4% |
| 2013 FY | 1.68 Billion KRW | -47.49% |
| 2013 Q2 | 2.29 Billion KRW | 280.85% |
| 2013 Q1 | 603 Million KRW | -81.19% |
| 2012 Q1 | 3.67 Billion KRW | 0.0% |
| 2012 FY | 3.2 Billion KRW | 96.03% |
| 2012 Q4 | 3.2 Billion KRW | 0.32% |
| 2012 Q3 | 3.19 Billion KRW | -8.48% |
| 2012 Q2 | 3.49 Billion KRW | -5.01% |
| 2011 FY | 1.63 Billion KRW | -40.8% |
| 2011 Q3 | 1.94 Billion KRW | -12.34% |
| 2011 Q2 | 2.21 Billion KRW | -10.99% |
| 2011 Q1 | 2.48 Billion KRW | -9.9% |
| 2010 Q1 | 1.13 Billion KRW | -30.74% |
| 2010 FY | 2.76 Billion KRW | 69.32% |
| 2010 Q4 | 2.76 Billion KRW | 166.65% |
| 2010 Q3 | 1.03 Billion KRW | -2.22% |
| 2010 Q2 | 1.05 Billion KRW | -6.24% |
| 2009 Q4 | 1.63 Billion KRW | -76.8% |
| 2009 FY | 1.63 Billion KRW | -75.72% |
| 2009 Q2 | 7.06 Billion KRW | 6.4% |
| 2009 Q1 | 6.64 Billion KRW | -1.12% |
| 2009 Q3 | 7.03 Billion KRW | -0.52% |
| 2008 Q1 | 6.94 Billion KRW | -1.6% |
| 2008 Q3 | 6.79 Billion KRW | -1.09% |
| 2008 FY | 6.71 Billion KRW | -4.79% |
| 2008 Q4 | 6.71 Billion KRW | -1.1% |
| 2008 Q2 | 6.86 Billion KRW | -1.08% |
| 2007 Q1 | 1.42 Billion KRW | 0.0% |
| 2007 Q3 | 698.62 Million KRW | -13.88% |
| 2007 Q2 | 811.18 Million KRW | -43.02% |
| 2007 FY | 7.05 Billion KRW | 0.0% |
| 2007 Q4 | 7.05 Billion KRW | 910.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -35.794% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 90.833% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 38.004% |
| HANDOK Inc. | 123.78 Billion KRW | 85.036% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -3793.367% |
| Yuhan Corporation | 60.23 Billion KRW | 69.249% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 88.566% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -18091.724% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 77.42% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -3037.747% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -206.156% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -47.188% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -1058.486% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -35.794% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -15376.821% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 84.692% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 42.117% |
| JW Holdings Corporation | 20.65 Billion KRW | 10.335% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -24.939% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 38.259% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 38.259% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -8359.229% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -3089.966% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 62.633% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -316.047% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -35.794% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 2.655% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 80.172% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 38.259% |
| Yuhan Corporation | 60.23 Billion KRW | 69.249% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -76.404% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 54.127% |
| Suheung Co., Ltd. | 74 Billion KRW | 74.972% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 38.259% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -344.541% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -68.962% |
| CKD Bio Corp. | 69.43 Billion KRW | 73.323% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 46.428% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -14.849% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -5932.254% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -8359.229% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 74.315% |
| Boryung Corporation | 151.7 Billion KRW | 87.791% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 76.412% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -206.156% |
| JW Lifescience Corporation | 168 Million KRW | -10925.245% |